Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancer cells by pristimerin

Liu,Yong  Bo; Gao,Xiaohua; Deeb,Dorrah; Brigolin,Chris; Zhang,Yiguan; Shaw,Jiajiu; Pindolia,Kirit; Gautam,Subhash  C.

doi:10.3892/ijo.2014.2561

Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancer cells by pristimerin

Authors:
- Yong Bo Liu
- Xiaohua Gao
- Dorrah Deeb
- Chris Brigolin
- Yiguan Zhang
- Jiajiu Shaw
- Kirit Pindolia
- Subhash C. Gautam
View Affiliations

Affiliations: Department of Surgery, Henry Ford Health System, Detroit, MI 48202, USA, Department of Medical Genetics, Henry Ford Health System, Detroit, MI 48202, USA, Department of Internal Medicine, Henry Ford Health System, Detroit, MI 48202, USA
Published online on: July 25, 2014 https://doi.org/10.3892/ijo.2014.2561
Pages: 1735-1741

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pristimerin (PM), a quinonemethide triterpenoid, is a promising anticancer agent with potent antiproliferative and apoptosis-inducing activities against cancer cell lines. However, the anticancer activity and mechanisms of PM in prostate cancer cells have not been adequately investigated. Here we report that the degradation of survivin plays an important role in the antiproliferative and proapoptotic effects of PM in carcinoma of the prostate (CaP) cell lines. Treatment with PM inhibited proliferation and induced apoptosis in LNCaP and PC-3 cells as characterized by the loss of cell viability and an increase in Annexin V-binding and cleavage of PARP-1, respectively. The antiproliferative and apoptosis-inducing effects of PM were associated with the inhibition of cell cycle regulatory proteins, antiapoptotic survivin and members of the Bcl-2 family. Data showed that response to PM is regulated by survivin since overexpression of survivin rendered CaP cells resistant to PM. Furthermore, downregulation of survivin by PM was mediated through the ubiquitin-proteasomal degradation. Together, these data demonstrate that pristimerin inhibits proliferation and induces apoptosis in CaP cells by abolishing survivin through the ubiquitin-proteasome pathway.

View Figures

View References

1	Buffa Filho W, Corsino J, Bolzani da SV, Furlan M, Pereira AM and Franca SC: Quantitative determination for cytotoxic Friedo-nor-oleanane derivatives from five morphological types of Maytenus ilicifolia(Celastraceae) by reverse-phase high-performance liquid chromatography. Phytochem Anal. 13:75–78. 2002.
2	Chang FR, Hayashi K, Chen IH, et al: Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii. J Nat Prod. 66:1416–1420. 2003. View Article : Google Scholar : PubMed/NCBI
3	Sassa H, Kogure K, Takaishi Y and Terada H: Structural basis of potent antiperoxidation activity of the triterpene celastrol in mitochondria: effect of negative membrane surface charge on lipid peroxidation. Free Radic Biol Med. 17:201–207. 1994. View Article : Google Scholar
4	Dirsch VM, Kiemer AK, Wagner H and Vollmar AM: The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages. Eur J Pharmacol. 336:211–217. 1997. View Article : Google Scholar
5	Figueiredo JN, Raz B and Sequin U: Novel quinone methides from Salacia kraussii with in vitro antimalarial activity. J Nat Prod. 61:718–723. 1998. View Article : Google Scholar : PubMed/NCBI
6	Costa PM, Ferreira PM, da Bolzani VS, et al: Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia ( Celastraceae) in human HL-60 cells. Toxicol In Vitro. 22:854–863. 2008. View Article : Google Scholar : PubMed/NCBI
7	Yang H, Landis-Piwowar KR, Lu D, et al: Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem. 103:234–244. 2008. View Article : Google Scholar : PubMed/NCBI
8	Yan YY, Bai JP, Xie Y, Yu JZ and Ma CG: The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction. Oncol Lett. 5:242–248. 2013.PubMed/NCBI
9	Lee JS, Yoon IS, Lee MS, et al: Anticancer activity of pristimerin in epidermal growth factor receptor 2-positive SKBR3 human breast cancer cells. Biol Pharm Bull. 36:316–325. 2013. View Article : Google Scholar : PubMed/NCBI
10	Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR and Wu YC: Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther. 4:1277–1285. 2005. View Article : Google Scholar : PubMed/NCBI
11	Lu Z, Jin Y, Chen C, Li J, Cao Q and Pan J: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer. 9:1122010. View Article : Google Scholar : PubMed/NCBI
12	Byun JY, Kim MJ, Eum DY, et al: Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol Pharmacol. 76:734–744. 2009. View Article : Google Scholar
13	Deeb D, Gao X, Liu YB, Pindolia K and Gautam SC: Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2. Int J Oncol. 44:1707–1715. 2014.PubMed/NCBI
14	Mu XM, Shi W, Sun LX, et al: Pristimerin inhibits breast cancer cell migration by up-regulating regulator of G protein signaling 4 expression. Asian Pac J Cancer Prev. 13:1097–1104. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mu X, Shi W, Sun L, Li H, Jiang Z and Zhang L: Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation. Molecules. 17:6854–6868. 2012. View Article : Google Scholar : PubMed/NCBI
16	Cooperberg MR, Park S and Carroll PR: Prostate cancer 2004: insights from the national disease registries. Oncology (Williston Park). 18:1239–1258. 2004.PubMed/NCBI
17	Prostate Cancer. National Cancer Institute, U.S. National Institutes of Health Cancer.gov. http:www.cancer.gov/cancer-topics/types/prostate. Accessed Feb 7, 2014
18	Garnick MB: Hormonal therapy in the management of prostate cancer: From Higgins to the present. Urology. 49:5–15. 1997. View Article : Google Scholar : PubMed/NCBI
19	Hanks GE: Long-term control of prostate cancer with radiation. Urol Clin North Amer. 23:605–616. 1996. View Article : Google Scholar : PubMed/NCBI
20	Liu Y, Gao X, Deeb D, Ali S and Gautam SC: Pristimerin induces apoptosis in prostate cancer cells by down-regulating Bcl-2 through ROS-dependent ubiquitin-proteasomal degradation pathway. J Carcinogen Mutagen. S6:005doi: 104172/2157–2518. S6–005. 2013.PubMed/NCBI
21	Wang Y, Zhou Y, Zhou H, et al: Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells. PLOS One. 7:e438262012. View Article : Google Scholar : PubMed/NCBI
22	Chao DT and Korsmeyer SJ: BCL-2 family: regulators of cell death. Annu Rev Immunol. 16:395–419. 1998. View Article : Google Scholar
23	Green DR and Reed JC: Mitochondria and apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar
24	Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999. View Article : Google Scholar : PubMed/NCBI
25	Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:5315–5320. 1998.PubMed/NCBI
26	Zhao J, Tenev T, Martins LM, Downward J and Lemoine NR: The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 113:4363–4371. 2000.PubMed/NCBI
27	Li F1, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by surviving. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI
28	Koepp DM, Harper JW and Elledge SJ: How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell. 97:431–434. 1999. View Article : Google Scholar : PubMed/NCBI
29	Aberle H, Bauer A, Stappert J, Kispert A and Kemler R: beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16:3797–3804. 1997. View Article : Google Scholar : PubMed/NCBI